跳至主要内容
临床试验/NCT01862458
NCT01862458撤回3 期

Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema

Children's Mercy Hospital Kansas City2 个研究点 分布在 1 个国家开始时间: 2016年1月1日最近更新:
适应症

试验速览

阶段
3 期
状态
撤回
发起方
试验地点
2
主要终点
Length of stay

研究概览

简要总结

The objective of this study is to scientifically evaluate a new substrate for fibrinolysis compared to our standard tPA.

The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the addition of DNAse.

The primary outcome variable between the two techniques will be length of hospitalization after initiation of treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
— 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients less than 18 years of age requiring an intervention for empyema by one of the following:
  • Septation or loculation seen on ultrasound or computed tomography or
  • Greater than 10,000 white blood cells identified on pleural tap

排除标准

  • Immunodeficiency process
  • Secondary diagnosis or condition that will keep them in the hospital beyond the empyema
  • Existing contraindications to chest tube
  • Documented allergy to one of the study medications

结局指标

主要结局

Length of stay

时间窗: 3 weeks

次要结局

未报告次要终点

研究者

发起方
Children's Mercy Hospital Kansas City
申办方类型
Other
责任方
Principal Investigator
主要研究者

Shawn St. Peter

Assoc Prof

Children's Mercy Hospital Kansas City

研究点 (2)

Loading locations...

相似试验